Ohio has invested millions of dollars in innovation districts in Cincinnati, Cleveland and Columbus. Already, 88 companies have been certified by the FDA to manufacture pharmaceuticals in Ohio, attracting jobs and talent and creating opportunities to partner with the state’s world-renowned medical centers and universities to further develop Ohio’s bio-ecosystem. Revenue lost by enactment of price setting on selected drugs could devastate the bioscience sector and thwart prospects for Ohio innovation districts just as they are showing great potential.
Companies in the Dayton area whose work is threatened include:
- Adare Pharma Solutions in Vandalia, a global technology-driven CDMO providing product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical industry.
- Alkermes in Wilmington, a fully-integrated global biopharmaceutical company focused on developing innovative medicines that aim to address unmet needs of people living with serious mental illness, addiction and cancer.
- Soin Neuroscience in Dayton, a pharmaceutical company founded by Dr. Amol Soin, a pain management physician, is developing low dose naltrexone to treat complex regional pain syndrome and has received an orphan drug designation from the FDA.
These and other innovative bioscience leaders are doing the important hard work and research to find and deliver effective cures and treatments needed by Ohioans and others with rare diseases, chronic diseases, and cancers. Their ability to address significant unmet needs would be crippled by enactment of drug price setting in the Build Back Better reconciliation bill, and that is a high cost none of us wants to pay.
Eddie Pauline is President & CEO for BioOhio.